Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

UBS Oncology Impact Fund (OIF) (Cayman Islands) (managed by MPM Capital)

The UBS Oncology Impact Fund is formed and registered in the Cayman Islands. The UBS Oncology Impact Fund is not FINMA approved and may be distributed in or from Switzerland to qualified investors only. Representative in Switzerland is UBS Fund Management (Switzerland) AG, a wholly owned subsidiary of UBS AG with registered office at Aeschenplatz 6, CH-4002 Basel. Paying agent is UBS Switzerland AG and all its branches in Switzerland. The legal documentation pertaining to the UBS Oncology Impact Fund, as well as the unaudited quarterly reports and audited annual financial statements can be obtained free of charge from the Swiss Representative or from the Administrator and the place of performance and jurisdiction shall be at the registered office of the Swiss Representative. *


Period Start 2016-04-01 established
  Group UBS (Group)
Products Industry UBS Oncology Impact Fund (Cayman Islands)
  Industry 2 cancer drug
Person Person Bardon, Christiana (UBS Oncology Impact Fund 201806 Managing Director)
Region Region United Kingdom (town unspecified)
  Country United Kingdom (GB)
  City n. a. 
    Address record changed: 2016-04-29
Basic data Currency USD
  Annual sales 471,000,000 (capital under management 2016-04-27)
    * Document for �About Section�: UBS AG. (4/27/16). "Press Release: UBS Raises Record $471m for Oncology Impact Fund". Zurich & Basel.
Record changed: 2019-02-23


Picture [LSUS] – The Business Web Portal 650x112px

More documents for UBS (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top